English (UK)
δΈζηAshley CAI
China Structural Reform Fund
MDEmily Cao
Trespa China Co., Ltd
Country ManagerMr. Jeff Cao
As a medical device software specialist, we help MedTech startups get to their next milestone faster and safer. We have 20 years of experience and 220 in-house engineers to back you up and get you to the finish line - getting your device to market.
see less
ARROWFAST
VP CHINA
Eric Chang
Kaitai Capital
Executive Director
Dr. Matthieu CHAREYRE
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Regulaxis
Chief Business Development Officer - Global Pharmaceutical Operations
Cheng Charles
β
We are founded by a team of experienced professionals and executives with extensive industry expertise and backed by the most connected and influential investors and partners in the business ecosystem.
Knightway Capital
PartnerMr Murthy Chavali
Satyarx Pharma Innovations Private Limited
CEO
Responsive Web Design powered by 